We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
InKine Pharmaceutical has announced positive results of the company's multicenter,
Phase III study of its next generation sodium phosphate tablet, INKP-102.
FDA has approved Vaccinia Immune Globulin Intravenous (VIGIV), the first intravenous
human plasma-derived product available to treat certain rare complications
of smallpox vaccination.
Spectrum Pharmaceuticals has acquired an exclusive worldwide license to develop
and commercialize endothelinB agonists for the treatment of cancer, including
treatment of solid tumors, from Chicago Labs, a privately held company.
Quetiapine, a drug commonly used in nursing homes to treat agitation and related
symptoms in people with Alzheimer's' disease actually worsens patients' illness,
speeding up their rate of decline significantly, says a paper published on
bmj.com.
Long-term intermittent treatment with Elidel Cream 1 percent in both adult
and pediatric patients provided control of the symptoms associated with atopic
dermatitis, commonly known as eczema, for up to 18 months, according to new
study results announced during the 63rd annual meeting of the American
Academy of Dermatology in New Orleans.
Millennium Pharmaceuticals has announced final results from a Phase I clinical
trial of MLN2704 in patients with advanced hormone-refractory prostate cancer.
New data presented at the recent American Academy of Dermatology (AAD) meeting
suggest that an insecticide-free treatment currently in development and moving
through the regulatory process in the U.S. and Canada may be an effective alternative
to existing insecticide-based products for the treatment of pediculosis capitis
(head lice).
Preliminary results of an ongoing Phase II study indicate that the psoriasis
treatment Amevive provides clinical improvement for patients with active psoriatic
arthritis.